Why the study?
Prostate cancer requires abundant lipids for development, but whether lipid-modifying factors such as PCSK9, ANGPTL3, and Lp(a) vary in men with prostate cancer had not been reported.
Population
35 men with locally advanced PCa Gleason 8 and 9 and 35 at-risk controls paired by age and BMI
Comparison
Men with PCa Gleason 8 and 9 vs at-risk cancer-free men
Design
Case-control study
Key result
Locally advanced Gleason 8 or 9 prostate cancer was not associated with significant changes in lipid profiles, PCSK9, ANGPTL3, or Lp(a) levels compared to at-risk cancer-free men.
Authors
Loading...
No differences in PCSK9, ANGPTL3, or Lp(a) levels in localized high-grade PCa versus controls; leaves open biomarker or therapeutic roles pending prospective studies.
Case-Control (n=70)
Lipid profiles and lipid-modifying factors such as PCSK9, ANGPTL3, and Lp(a) do not significantly differ between men with high-grade localized prostate cancer and at-risk controls.
Chong et al. (2025) conducted a case-control in Prostate cancer (n=70). Locally advanced prostate cancer (Gleason 8 or 9) vs. At-risk but cancer-free men was evaluated on Lipid profiles, PCSK9, ANGPTL3, and Lp(a) levels. Locally advanced Gleason 8 or 9 prostate cancer was not associated with significant changes in lipid profiles, PCSK9, ANGPTL3, or Lp(a) levels compared to at-risk cancer-free men.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: